Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases

Figures & data

Figure 1 Flow chart of cohort definition.

Figure 2 The distribution of the study population stratified by treatment assignment 1 year before the index date (A: VKA cohort; B: NOAC cohort).

Table 1 Baseline Characteristics Among VKA And- NOAC-Naïve Users, Stratification According To Therapies Used During Pre-ID Period

Baseline Characteristics*	VKA-Naïve Users, OAC Naïve	NOAC-Naïve Users, OAC Naïve	p Value
Patients n (%)	3,435	911
Age, years mean (SD)	75.4 (10.6)	77.4 (10.2)	<0.001
Men, n (%)	53.8	49.7	0.029
Comorbidities, (%)
Hypertension	19.5	18.7	0.579
Chronic kidney disease	6.4	3.1	<0.001
Coronary artery disease	8.1	5.4	0.005
Heart failure	25.9	16.6	<0.001
Stroke	13.7	25.9	<0.001
Intracranial hemorrhage	0.5	0.4	0.916
Major bleeding	1.7	1.8	0.936
Myocardial infarction	6.1	3.5	0.002
Medication use, (%)
Betablockers	41.5	46.3	0.009
Calcium channel blockers	27.4	25.9	0.359
Diuretics	32.4	31.7	0.685
Other antihypertensive	57.5	63.4	0.001
Measures of overall health status
Number of unique medications, mean (SD)	4.3 (2.1)	4.4 (1.9)	0.168
Number of hospitalisations observed, mean (SD)	1.4 (1.2)	1.3 (1.0)	<0.001
Number of physician visits observed, mean (SD)	3.0 (3.8)	2.8 (3.4)	0.058
Charlson index, (%)			0.179
Low (0–1)	53.9	53.3
Intermediate (2–3)	36.5	38.9
High (≥ 4)	9.5	7.8
HAS BLED, (%)			0.007
Low (0–1)	17.9	13.6
Intermediate (2)	27.8	28.0
High (≥ 3)	54.3	58.4
CHA2Ds2 VASc, (%)			<0.001
Low (0–3)	47.9	41.7
Intermediate (4)	25.7	25.0
High (≥5)	26.3	33.3

Notes: *Evaluated in the 1 year prior to the index date.

Figure 3 Use of antiplatelet agents among OAC-naïve users during the baseline and follow-up period.

Figure 4 Adherence to NOAC treatment during the first 12 months after the index-date.

Table 2 Incidence Of Bleeding Events

	VKA (N)	NOAC (N)
Patients	6,155	927
Patients with events (%)	196 (3.2)	4 (0.4)
Events	229	5
Person-years of follow-up	18,740	878
Incidence rate/1,000-person years	10.46	4.55
Incidence rate of GI bleeding events/1,000-person years	4.98	3.41

Notes: Analysis made on 7082 patients with the same class during the follow-up period. Bleeding events have been evaluated during the follow-up period.

Abbreviations: VKA, vitamin K antagonist; NOAC, non-vitamin K oral anticoagulant agents; GI, gastrointestinal.

Figure 5 Total cost during the 1-year after the index-date.